"Unknown risks" of non-steroid topical medications for atopic dermatitis

International Journal of Dermatology

Volumn 46, Issue 6, 2007, Pages 656-658

  Mcneill, Anne Marie ^a   Koo, John Y M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; MOMETASONE FUROATE; NONSTEROID ANTIINFLAMMATORY AGENT; PIMECROLIMUS; STEROID; TACROLIMUS; ULOBETASOL PROPIONATE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; B CELL LYMPHOMA; BURNING SENSATION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FLU LIKE SYNDROME; HEALTH HAZARD; HUMAN; IMMUNOMODULATION; NONHUMAN; SKIN ATROPHY; SKIN BURNING SENSATION; SPECIES DIFFERENCE; STRIA; TELANGIECTASIA;

ADMINISTRATION, TOPICAL; ANIMALS; DERMATITIS, ATOPIC; DRUG TOXICITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; SKIN ABSORPTION; SKIN NEOPLASMS; TACROLIMUS; ULTRAVIOLET RAYS;

EID: 34250369619     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.02306.x     Document Type: Article

References (10)

1. Package Insert. Protopic (Tacrolimus) Ointment 0. 03%, 0.1%. Deerfield, IL: Fujisawa Healthcare Inc., December 2000.
2. Soter NA, Fleischer AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety. J Am Acad Dermatol 2001; 44: S39-S46.
3. Haseman JK, Hailey JR, Morris RW. Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol Pathol 1998; 26: 428-441.
4. Candra M, Frith CH. Spontaneous neoplasms in B6C3F1 mice. Toxicol Lett 1992; 60: 91-98.
5. Spalding JW, French JE, Stasiewicz S, et al. Responses of transgenic mouse lines p53 (+/-) and Tg. AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci 2000; 53: 213-223.
6. Package Insert. Nutracort (Hydrocortisone) Lotions 1%, 2.5%. San Antonio, TX: Healthpoint, 2004.
7. Package Insert. Ultravate (Halobetasol Propionate) Ointment 0.05%. Buffalo, NY: Westwood Squibb Pharmaceuticals Inc., 2004.
8. Package Insert. Elocon (Mometasone Furoate) Lotion 0.1%. Kenilworth, NJ: Schering Corporation, 1999.
9. Karagas MR, Cushing GL, Greenberg ER, et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85: 683-686.
10. Jaracz E. Manager of Medical Information. Fujisawa Heathcare Inc., 2001. Personal communication.